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Screening cancer patients' families with the distress thermometer
(DT): a validation study
Abstract
Although family members of cancer patients are at great risk of experiencing psychological distress,
clinical tools to assist with recognizing and intervening with appropriate psychosocial care are sparse.
This study reports on the first validation of the distress thermometer (DT) as a screening instrument for
symptoms of depression and anxiety in family members of cancer patients. The DT was administered
with the Hospital Anxiety and Depression Scale (HADS) in a sample of 321 family members. Receiver
operating characteristics (ROC) demonstrated that the DT has good diagnostic utility relative to the
HADS (area under the curve= 0.88 relative to the HADS anxiety scale; 0.84 relative to the HADS
depression scale, respectively). The ROC curves indicate that using a cut-off of 4/5 maximizes
sensitivity (86.2% HADS anxiety scale; 88.2% HADS depression scale) and specificity (71.2% HADS
anxiety scale; 67.6% HADS depression scale); however, the alternative lower cut-off of 3/4 increases
sensitivity (94.1% for both scales) and hence reduces the risk of missing distressed family members
(specificity is 62.9% for HADS anxiety scale; 59.1% for HADS depression scale). The results offer
validation of the DT for screening family members of cancer patients and support its use for clinical
assessment. Distress screening with DT for family members of cancer patients is a promising and
efficient approach to integrating family members in the program of care and provides the first step
toward meeting their unmet needs with referral for supportive services.
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ABSTRACT 
Although family members of cancer patients are at great risk for experiencing 
psychological distress clinical tools for to assist with recognizing and intervening with 
appropriate psychosocial care are sparse. This study reports on the first validation of the 
Distress Thermometer (DT) as a screening instrument for symptoms of depression and 
anxiety in family members of cancer patients. The DT was administered with the Hospital 
Anxiety and Depression Scale (HADS) in a sample of 321 family members. Receiver 
Operating Characteristics (ROC) demonstrated that the DT has good diagnostic utility 
relative to the HADS (area under the curve= 0.88 relative to the HADS anxiety scale; 0.84 
relative to the HADS depression scale, respectively). The ROC curves indicate that using a 
cut-off of 4/5 maximizes sensitivity (86.2% HADS anxiety scale; 88.2% HADS depression 
scale) and specificity (71.2% HADS anxiety scale; 67.6% HADS depression scale), 
however the alternative lower cut-off of 3/4 increases sensitivity (94.1% for both scales) 
and hence reduces the risk of missing distressed family members (specificity is 62.9% for 
HADS anxiety scale; 59.1% for HADS depression scale). The results offer validation of the 
DT for screening family members of cancer patients and support its use for clinical 
assessment. Distress screening with DT for family members of cancer patients is a 
promising and efficient approach to integrating family members in the program of care and 
provides the first step toward meeting their unmet needs with referral for supportive 
services. 
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INTRODUCTION 
  The prevalence of various forms of clinically significant psychological distress in 
cancer patients has been well documented [1-4]. Distress among family members of cancer 
patients has also received significant attention by psychooncology researchers [2, 5, 6]. In 
recent years sophisticated treatments and therapies have increased rates of survival and 
have lengthened the timeframe for chronic disease processes, giving rise to new 
psychological issues for patients and their families [7]. With a host of new treatment 
possibilities, care for cancer patients has largely shifted from inpatient to outpatient 
settings; as a result, families are exposed to new burdens related to caring for cancer 
patients at home [8]. Key family members often provide emotional and logistical support to 
the patient [6, 9, 10], and family members’ own psychological adjustment to these 
challenges can have a significant effect on their ability to support the patient [11, 12]. 
Family members’ psychological adjustment has also been found to influence patients’ 
adjustment to cancer [13, 14]. Research suggests that psychological distress is as prominent 
for family members of cancer patients as it is for the patients themselves: a recent review of 
research on psychological distress in cancer patients and their families reported prevalence 
of distress in both family members and patients as ranging from 15% to 50% [2]; and a 
meta-analytic investigation of 21 studies of patient and family member distress levels 
reported that family members were as likely to experience psychological distress as cancer 
patients themselves [15].  
  Increased awareness of psychological distress in cancer patients has 
prompted hospitals and cancer clinics to initiate distress screening programs; these 
programs have applied a variety of instruments to measure psychological sequelae of the 
disease [16]. There are a number of barriers to measuring psychological distress in clinical 
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oncology practice, including the time and labor required to administer long or complex 
screening instruments. Recognizing these constraints, the National Comprehensive Cancer 
Network (NCCN) has recommended the use of the Distress Thermometer (DT), a single-
item self-report measure of distress, in oncology clinics [17]. The DT is presented as a 10-
point scale in a thermometer format and was originally developed by Roth and colleagues 
[18]. The use of the tool was notably championed by the Memorial Sloan Kettering Cancer 
Centre team. 
 Pooled results of the accuracy of the DT have recently been published [19]. Validity 
of DT has been examined for outpatient groups with various forms of cancer and patients in 
rehabilitation, as well as for different languages [18, 20, 21] Validity of DT has also been 
examined for childhood cancer survivors [22]. However, no research to date has examined 
validity of DT in a family member population. By validating DT in a family member 
population, the instrument’s utility may be expanded to meet the increasing demand for 
efficient screening of family members; given the relationship between caregiver distress 
and patient adjustment to cancer, the benefit of the screening may also accrue to patients 
themselves. 
The following study examines the validity of the distress thermometer as an 
instrument for detecting emotional distress in family members – defined as clinically 
significant symptoms of depression and anxiety according to the Hospital Depression and 
Anxiety Scale (HADS). Analyzing a sample of 321 family members of cancer patients, 
data collected with the DT are compared to data collected using the HADS, a self-report 
measure of depression and anxiety. In addition, the study examines the sensitivity and 
specificity of the DT by considering different cut-off points in relation to the HADS.  
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METHOD{ TC “METHOD” /l  1 } 
Data used in this report is derived from a multi-site study that included four oncology units 
in the German-speaking region of Zurich, Switzerland. The study investigated cancer 
outpatients’ and designated family members’ psychosocial well-being and their experience 
with psychosocial care during the course of the disease. The present report focuses on 
family members only.  
Procedure 
Oncology patients were identified on the basis of scheduled outpatient visits with their 
oncologist at one of the participating oncology units between July 1st and December 31st, 
2005. On the advice of clinic staff who reviewed the patient lists, individuals were 
identified and excluded from participation who were not in sufficient command of the 
German language or were considered too weak and incapacitated to complete the 
questionnaire and thus to provide reliable and valid responses. No exclusion criteria were 
used with respect to the location of the cancer or the stage of the disease in patients. 
Patients identified as eligible for participation were contacted by mail and asked to 
distribute one of the two questionnaires to the individual they designated as the family 
member closest to them during the course of their disease. Hence DT and HADS were 
applied by mail and not personally approached by medical staff at the hospital. Patients and 
family members were provided with separate postage-paid envelopes and asked to fill out 
the questionnaire individually.  
 
Participants 
Out of 1,234 total family members, an overall response rate of 34.6% (427 questionnaires) 
was achieved. Of the 427 returned questionnaires, 321 were included in the statistical 
analysis. 44 surveys were excluded due to incompleteness of responses (5), recent death of 
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the patient (10), and because the patient declined participation and therefore patient-
reported disease and treatment information was not available (29). 
Individuals who declined to participate were asked to answer a brief set of questions 
regarding the reason for their refusal and send it back in lieu of the completed 
questionnaire. Sixty-two family members provided a statement on their decision to opt out. 
The top two reasons cited for opting out of participation were that filling out the survey 
would be too distressing or exhausting (28 family members) and that providing personal 
statements was undesirable (14 family members). No personal or demographic information 
was gathered from individuals who declined to participate out of respect for their requested 
anonymity. In sum, with respect to completed surveys, a response rate of 29.5% (response 
rate with respect to completion among patients: 36.6%) was achieved.  
All study documents were approved by the ethics commission of Zurich’s 
university hospital and by the institutions that participated in the study.  
 
Measures 
In order to distinguish the two categories ‘healthy’ and ‘sick’ with a screening test, a 
threshold score is necessary (usually called cut-off). For clarity, we will use a two-number 
expression for cut-off, such as 4/5, indicating that the threshold lies between these two 
numbers. This notation avoids the ambiguity that may arise with the use of a single number 
(e.g. “a cut-off of 8 was used”) [23]. 
Hospital Anxiety and Depression Scale (HADS) [24]. The HADS is a 14 item 
questionnaire widely used to detect anxiety and depression in physically ill patients, 
including cancer patients [25]. Studies have used the HADS as a criterion measure to 
validate the DT among different groups of cancer patients before [18, 26, 27]; the HADS 
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has also been applied to measure and compare symptoms of psychological distress such as 
anxiety and depression among family members of cancer patients [28-30]. The HADS is 
self-explanatory and short; investigators have also used the HADS in mailed surveys in 
other studies [29, 31]. 
The HADS is divided into two subscales with seven questions pertaining to 
symptoms associated with anxiety and seven pertaining to symptoms of depression. Using 
a four-point Likert-like scale patients rate how they have been feeling during the previous 
week. The total score for each subscale ranges from 0 to 21. As recommended by 
Herrmann in his validation study of the German language version of the HADS [32] the 
following standard case rule for the German translation of the HADS was adopted: 
Individuals with scores ≥ 9 (cut-off 8/9) on the depression subscale were considered to 
have significant depression symptoms and classified as a “depression case.” Individuals 
with scores ≥11 (cut-off 10/11) on the anxiety subscale were considered to have significant 
symptoms of anxiety and classified as “anxiety case”. Several studies have adopted this 
case rule with German speaking samples [32, 33].  
Distress Thermometer (DT). Subjective distress in family members was assessed 
using the Distress Thermometer developed by Roth and colleagues [18]. Individuals were 
asked to rate how distressed they felt in the previous week on a single-item scale from zero 
(not distressed) to ten (extremely distressed). We utilized the original version of the DT 
without adding the problem list suggested by the NCCN Clinical Practice Guidelines for 
Distress Management for cancer patients, since a considerable part of the problem list is 
dedicated to various physical complaints associated with cancer or its treatment. Previous 
examinations reported that the DT shows agreement with established distress measures 
(e.g. HADS, BSI) in various groups of cancer patients. In a thorough examination Jacobsen 
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[26] suggested using a cut-off of 3/4 on the DT whereas others [18, 20, 27]  suggested the 
case rule of 4/5. The NCCN Guidelines [17] changed their recommendation from 4/5 to a 
cut-off of 3/4. No investigation on psychometric properties of the DT exists for the 
population of family members.  
Demographic variables. The participants reported their age gender, education level, 
living situation (with/without partner), and household income as well as their relation to the 
cancer patient. 
Medical variables. Medical information was derived from patients’ self-reports. 
These included: The location of the patients’ disease and their cancer type; treatments 
undergone since the cancer diagnosis; time since the first diagnosis they received and 
potential later diagnosis of recurrence and new tumours; current treatment status and stage 
of the disease. 
 
Statistical Analysis 
Statistical analyses were conducted using ‘R’[34]. The association of each HADS scale and 
the DT was described by reporting Pearson correlations. Family members mean DT scores 
and the frequency distribution of the DT were reported to facilitate comparison with other 
samples.  
The main research question of classification agreement between the DT and HADS 
was examined by determining the degree to which both measures identified subjects with 
significantly elevated levels of psychological distress. Agreement between the HADS 
scales and the DT was quantified by calculating Receiver Operating Characteristics (ROC), 
sensitivity and specificity. The sensitivity of an instrument refers to the degree to which a 
measure captures evidence of a condition or “disease”, and thus offers a positive screening 
 8 
  9 
result for individuals who actually have the condition [35]. Specificity measures the degree 
to which an instrument accurately identifies patients in whom the condition or disease is 
not present [35]. The analysis generates a curve, and the Area Under the Curve (AUC) 
represents the diagnostic utility of a test across the full range of scores[36, 37].  
Improvement in diagnostic accuracy beyond chance is reflected in an AUC greater than 0.5 
[37, 38]. Based on previous recommendations [39, 40], this study designated an AUC value 
≥ .80 as an indication of good discrimination, and an AUC value ≥ .90 as indicative of 
excellent discrimination. The point on the ROC curve in the upper-left-most corner 
represents the cut-off score that produces the most precise balance between sensitivity and 
specificity, and thus represents the screening score that will correctly identify the greatest 
proportion of cases [41, 42]. Therefore using this cut-off maximizes the proportion of 
subjects correctly classified by screening. However choosing this cut-off may not be 
optimal for screening application because it places equal weight on false positives and false 
negatives. Clinical screening programs often give more weight to increasing sensitivity [37, 
43] to accurately ensure that most, if not all, of the patients with the condition are identified 
by the screening instrument. 
 
RESULTS 
{ TC “RESULTS” /l  1 } 
Demographic information and disease characteristics of the sample (N=321). 
Two hundred twenty-five (70.1%) of the study participants were spouses or partners 
of cancer patients, 94 (29.3%) were other types of close family members such as adult 
siblings, adult children, or parents of adult patients (0.6% or 2 missing). One hundred 
eighty-eight (58.6%) family members were female (4.0% or 13 missing) and study 
participants’ age ranged from 18-85 years (mean: 55.9; SD: 14.0; 6.5% or 18 missing). The 
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vast majority was living with a partner (317 or 91.9%; 1.2% or 4 missing). About a third of 
the family members (114 or 35.5%) report a monthly household income of 6’000 to 9’999 
Swiss Francs, another third (106 or 33.0%) an income of 3’000 to 5’999 Swiss Francs, 
respectively. The remaining third is evenly divided in lower or higher income than these 
two groups (5.0% or 16 missing). The majority of family members completed an 
apprenticeship (161 individuals or 50.2%) while another 30 (9.3%) have an obligatory 
school degree and another 38 (11.8%) individuals have a university degree. The remaining 
82 persons (25.7%) have different other degrees (3.1% or 10 missing). 
Sociodemographic information of patients was comparable to their family 
members: half of the patients were male (162 or 50.5%; 2.8% or 9 missing) and mean age 
was at 57.2 years (SD: 14.7; range 19-87; 4.7% or 15 missing). 85.7 % or 275 of the 
patients were living in a partnership (1.2% or 4 missing). Disease-related information 
derived from the matched patients’ surveys is listed in table 1. All categories of diagnosis 
comprising fewer than twenty patients have been summarized as “other” (including: 
myeloma, liver cancer, testicular cancer, ovarian cancer, pancreatic cancer, stomach cancer, 
prostate cancer, and more). Some patients were diagnosed with more than one cancer type. 
“Time since diagnosis” refers to the time elapsed since a patient received his or her latest 
diagnosis. Months passed since diagnosis ranges from one to 264 with a mean of 30.7 
months (1.9 or 6 missing). 
Distribution of HADS Scores and Distress Thermometer scores. 
Fifty-one (15.8%) family members experience clinically relevant symptoms of 
anxiety (cut-off 10/11) while 34 (10.6%) family members report to suffer symptoms of 
depression (cut-off 8/9) according to the HADS scales. Out of these 85 family members 
reporting relevant anxiety or depression symptoms, 22 individuals experienced concurrent 
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symptoms of depression and anxiety, therefore suffered comorbid anxiety and depression 
according to the HADS. Table 2 shows the frequency distribution of scores on the DT. The 
mean value on the DT was 3.67 with a median of 3.00. One hundred and sixty-three 
(53.1%) of the family members reported low distress levels (0-3). A smaller number of 
individuals (88 [29.2%]), indicated moderate levels of distress (4-6), with another 55 (18%) 
family members reporting severe distress levels (7-10). 
 
 
Establishing cut-off scores in comparison to HADS scales. 
Correlation of DT scores and HADS scores were found to be moderate to high 
suggesting that both instruments measure a similar construct (with HADS depression scale 
r = 0.69 / with HADS anxiety scale r = 0.65).  
In the current study, the area under the curve (AUC) was 0.85 using the HADS 
anxiety scale as the criterion measure, and 0.81 using the HADS depression scale as the 
criterion measure (Figure 1 and 2). The AUC scores are indicating a good accuracy of 
discrimination of the DT relative to both HADS scales. Looking at the graphical 
representation of sensitivity and specificity, it becomes evident that several potential cut-
off scores on the DT should be examined more closely for its diagnostic utility. Table 3 
displays the sensitivity and specificity values for selected cut-off scores on the DT along 
with positive and negative predictive values. A cut-off of 4/5 on the DT would have 86.2% 
sensitivity for the HADS anxiety scale and 88.2% sensitivity for the HADS depression 
scale, thereby ensuring that 86 subjects out of 100 meeting the HADS anxiety and 88 
subjects out of 100 meeting the HADS depression criteria for elevated symptoms on either 
of the scales would be identified as clinical cases on the DT. 
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Using a lower cut-off of 3/4 as suggested by the NCCN Guidelines for Distress 
Management for patients [17] increases the number of identified positive cases on the 
HADS scales (sensitivity; 94.1% for both HADS anxiety scale and depression scale). At 
this cut-off, the specificity is at 62.9% with HADS anxiety scale and at 59.1% with the 
HADS depression scale, resulting in quite a number of family members being identified as 
distressed on the DT even though they were not actually significantly distressed on the 
HADS scales (false positives). The cut-off that achieves maximum sensitivity while 
maintaining an adequate level of specificity is a DT score of 4/5 whereas a DT of 3/4 
increases the number of truly identified individuals (sensitivity). 
DISCUSSION 
{ TC “DISCUSSION” /l  1 } 
The results of this study support the use of the DT for screening family members of 
cancer patients for symptoms of depression and anxiety. The reported correlations of 
HADS and DT (r from .65 to .69) suggest good construct validity for scores ranging from 
slight to strong symptomatology. In the sample of family members the DT proved to have 
good to very good overall discrimination (AUC = 0.85 for HADS anxiety scale and AUC = 
0.81 for HADS depression scale) demonstrating the ability to detect cases versus non-cases 
according to the HADS scales.  These scores measuring accuracy of discrimination are 
higher than previous validation studies of DT with other cancer patient populations e.g. 
[18, 20, 26, 44] and childhood cancer survivors [22].  
ROC analysis identified two potential cut-off scores that may be useful for clinical 
application in evaluating family members’ distress. It has been suggested that a range of 
DT cut-off scores be used in clinical settings [20]; ROC analysis quantifies the trade-offs 
associated with using various cut-off scores to identify distressed family members. In this 
sample, a cut-off of DT 4/5 maximized the balance between true positive (sensitivity) and 
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false positive (specificity) rates of identification and resulted in the highest agreement 
between the two measures. Specifically the cut-off of 4/5 presented a sensitivity of 86.2% 
for the HADS anxiety scale and 88.2% for the HADS depression scale. Specificity rates for 
the HADS anxiety scale was 71.2% whereas for the HADS depression scale specificity was 
67.6%.  
A DT cut-off of 3/4 by contrast sensitivity for both, the HADS anxiety and 
depression scale was 94.1%. Sensitivity for the HADS anxiety scale was 62.9% and for 
HADS depression scale was 59.1%. This cut-off score therefore increases the risk of 
identifying as distressed some family members who are non-distressed, while maximizing 
the identification of distressed family members. 
The consequences of false positive screenings may be practical -- e.g., the burden of 
further assessment and the cost of attending to family members who may not require 
intervention. The consequences of false negative screenings - therefore failing to identify 
truly distressed family members - may have more significant clinical impact. These and 
other factors specific to a given clinical or research setting can be considered when 
determining the appropriate cut-off score to use in a given situation. Therefore, we 
advocate use of a cut-off of 3/4 or 4/5 for screening family members of cancer patients 
depending on the goals of screening and the balance between maximizing sensitivity and 
specificity appropriate to the application and setting; Cut-off scores, with the 
recommendation to attend to issues of the impact of data on specificity and sensitivity. 
The findings of our study illustrate the strength of psychometric properties of the 
DT in the investigated group of cancer patients’ family members. The greater accuracy of 
discrimination reported for DT in this sample (as compared to patient samples) may also 
reflect differences between families and patients in the experience or meaning of “distress”. 
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Questions of the relationships and differences between family and cancer patient 
experiences of distress as measured by DT can be examined in future research. 
Limitations: This report accounts on the first attempt to validate the DT in a sample of 
family members of ambulatory cancer patients. The relatively large sample size is a 
strength of the study, as is the use of HADS as a criterion measure, given previously 
published work using this instrument. However, a limitation of the investigation includes 
the sole use of HADS as a criterion measure; future studies could extend understanding of 
validity of DT by using additional criterion measures. Another limitation we need to 
address is that a non-standard version of the HADS with a non-standard cut-off score 
established for the German language version was used in this investigation. Future studies 
will need to replicate the findings before assuming the findings are the same in the English 
language version. Further, while the study reports on a sample with a wide range of distress 
scores, the mean distress level was not high. Therefore, generalizability to a highly 
distressed population needs to be further proven. The ways – thus the receipt of the survey 
being dependent on the patient wanting to hand moderate rate of participation in the study 
should also be considered as a limitation effective the generalizability of the findings. 
Lower than expected participation can be attributed, in part, to the following factors: the 
survey could reach a family member only in indirect it to a close person. Patients were sent 
a survey but were not personally approached by medical staff at the hospital nor over the 
telephone; and the survey was not accompanied by a pre-notification letter nor was a 
reminder letter sent; and last but not least, completing the questionnaire was a fairly time-
consuming process and required individuals to reflect on potentially difficult emotions. 
Given the personal matters involved in the survey, family members may also have been 
concerned about the confidentiality of the information. Additionally, in contrast to clinical 
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trials that test some potentially beneficial treatment, family members may see no personal 
benefit for them or the patient to be derived from completing a questionnaire. However a 
recent review of published non-response bias studies documented that even a moderate or 
low response rate does not necessarily imply high bias [45] . Last but not least using both, 
the HADS and DT in a mail survey may also have the effect of generating higher 
concordance between the two measures. Conclusion. Since family members often stay in 
the background of cancer care and attention is drawn to patients, their needs may be 
systematically neglected [13, 46-49]. Family members themselves are often reluctant to 
address their own distress resulting in potential impairment of long-term role functioning 
and harmful consequences for the whole family [50]. Identification of family members in 
need is the first step in integrating family members in the program of care and meeting 
their needs with referral for supportive services.  
 Validity of the Distress Thermometer (DT) has been demonstrated in this study. DT 
can effectively be used to identify psychological distress in the form of depression and 
anxiety in family members of cancer patients. Distress screening with DT for family 
members of cancer patients is a promising and efficient approach to extending a program of 
care for cancer patients to their families, offering benefit to both family members and 
patients themselves. Following the path of screening family members with the DT responds 
to a growing international emphasis on including families of cancer patients in cancer care 
[11, 50-55].  In a continuation of this investigation our study group will be reporting on 
patient and partner DT data and the proposal for a more practical family-focused approach 
of psychosocial care in cancer clinics including distress screening with the DT. 
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Table 1 
Disease Characteristics of the Patients 
 N    % 
Cancer Site 
Breast      30   9.3 
Intestinal     43  13.4 
Skin      46  14.3 
Leukemia     23    7.2 
Lung       32  10.0 
Lymphoma     83  25.9 
Other     113  35.1 
Treatment 
Chemotherapy    254  79.1 
Surgery    168  52.3 
Radiotherapy    121  37.7 
Other      77  23.9 
Treatment Status 
In-treatment    105  32.7 
Off-treatment     168  52.3 
Palliative Stage      9    2.8 
Status Unknown    39  12.1 
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Table 2 
Frequency Distribution of the DT Scores of Family Members 
    Distress Thermometer 
Score on the DT No. of Family Members %   
 0    30     9.8 
 1    50   16.3 
 2    44   14.3 
 3    39   12.7 
 4    25     8.1 
 5    41   13.4 
 6    22     7.1 
 7    24     7.8 
 8    22     7.1 
 9      4     1.3 
10      5     1.6 
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Figure Caption 
Figure 1 
ROC Curve for the Distress Thermometer Compared to the HADS Anxiety Scale
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Figure Caption 
Figure 2 
ROC Curve for the Distress Thermometer Compared to the HADS Depression Scale 
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Table 3 
Cut-off on the DT and the Corresponding Sensitivity and Specificity Rates along with 
corresponding Positive (PPV) and Negative Predictive Values (NPV) Relative to the HADS 
Anxiety and Depression Scale  
Distress Thermometer 
HADS Scale  Cut-off Sensitivity Specificity PPV  NPV 
Anxiety  2/3  100.0% 48.8%  0.28  1 
3/4  94.1%  62.9%  0.33  0.98 
4/5  86.2%  71.2%  0.37  0.96 
5/6  74.5%  85.0%  0.50  0.94 
Depression   2/3  94.1%  44.8%  0.17  0.98 
3/4  94.1%  59.1%  0.22  0.99 
4/5  88.2%  67.6%  0.25  0.98 
5/6  73.5%  80.8%  0.33  0.96 
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